Article
Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression.
Anticancer research - 1 Aug 2022
Janpipatkul Keatdamrong, Panvongsa Wittaya, Worakitchanon Wittawin, Reungwetwattana Thanyanan, Chairoungdua Arthit
Abstract excerpt
BACKGROUND/AIM: Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. Unfortunately, most patients quickly develop an acquired resistance to EGFR-TKIs. However, the effects of NSCLC harboring EGFR-T790M mutation on aggressive NSCLC phenotypes is still unclear. This study aimed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
